JPMorgan Chase & Co. reissued their overweight rating on shares of Shire PLC (LON:SHP) in a research note issued to investors on Tuesday.

SHP has been the subject of a number of other research reports. Shore Capital reissued a buy rating on shares of Shire PLC in a research note on Tuesday, August 30th. Deutsche Bank AG reaffirmed a buy rating and issued a GBX 6,000 ($74.32) price target on shares of Shire PLC in a research note on Monday, September 19th. Jefferies Group reaffirmed a buy rating and issued a GBX 6,600 ($81.75) price target on shares of Shire PLC in a research note on Monday, October 31st. Goldman Sachs Group Inc. reaffirmed a buy rating and issued a GBX 6,300 ($78.04) price target on shares of Shire PLC in a research note on Wednesday, October 12th. Finally, BNP Paribas reaffirmed an outperform rating and issued a GBX 5,900 ($73.08) price target on shares of Shire PLC in a research note on Friday, September 30th. One investment analyst has rated the stock with a sell rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of GBX 5,992.27 ($74.23).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) opened at 4913.00 on Tuesday. The company’s market capitalization is GBX 44.23 billion. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,562.83. The stock has a 50 day moving average of GBX 4,980.23 and a 200-day moving average of GBX 4,690.21.

In other news, insider Dominic Blakemore purchased 133 shares of the company’s stock in a transaction on Friday, September 30th. The stock was acquired at an average price of GBX 5,010 ($62.06) per share, with a total value of £6,663.30 ($8,253.81).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.